Although diffuse large B-cell lymphoma(DLBCL)is considered as a curable disease after standard immunochemotherapy,approximately30%of patients would succumb to short survival.To date,clinical presentations and gene exp...Although diffuse large B-cell lymphoma(DLBCL)is considered as a curable disease after standard immunochemotherapy,approximately30%of patients would succumb to short survival.To date,clinical presentations and gene expressions have been used to identify these high-risk patients.展开更多
Around 10%-30%of non-small cell lung cancer(NSCLC)patients harbored epidermal growth factor receptor(EGFR)mutations,with L858R and exon-19 deletions(19-Del)accounting for 90%of cases.EGFR tyrosine kinase inhibitors(TK...Around 10%-30%of non-small cell lung cancer(NSCLC)patients harbored epidermal growth factor receptor(EGFR)mutations,with L858R and exon-19 deletions(19-Del)accounting for 90%of cases.EGFR tyrosine kinase inhibitors(TKls)showed significant efficacy against common EGFR mutations.However,the therapeutic relevance of uncommon EGFR mutations remained insufficiently investigated.EGFR fusions are extremely rare(0.05%-0.13%)in NSCLC,and Konduri group reported only 5 EGFR fusions from 10,097 patients.i2Additional EGFR'fusions were reported in NSCLC,3,4 all of which were oncogenic drivers and sensitive to EGFR TKls.Herein,we reported an NSCLC patient with leptomeningeal metastasis(LM)who acquired a novel EGFR-SEPT14 fusion during TKI resistance and showed promising responses to certain EGFR TKls and intrathecal pemetrexed(IP).展开更多
基金This work was supported by Zhejiang Provincial Natural Science Foundation of China(No.LY19H080009,and LY20H080008)Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province(China)(No.JBZX-201904)+1 种基金This study is also supported by the major projects of Zhejiang Provincial Department of Science and Technology 491010+J3210NZJ(China)the Research Project of Jinan Microecological Biomedicine Shandong Laboratory,Jinan,China.
文摘Although diffuse large B-cell lymphoma(DLBCL)is considered as a curable disease after standard immunochemotherapy,approximately30%of patients would succumb to short survival.To date,clinical presentations and gene expressions have been used to identify these high-risk patients.
基金supported by the Major Science&Technology Project of Zhejiang Province,China(No.2020C03058)Key Disciplines of Traditional Chinese Medicine in Zhejiang Province,China(No.2017-XKA33)+1 种基金Research Center of Pulmonary Oncology of Zhejiang Province,China(No.JBZX-202007)Science and Technology Plan Project of Wenling,Zhejiang Province,China(No.2020S0180105s).
文摘Around 10%-30%of non-small cell lung cancer(NSCLC)patients harbored epidermal growth factor receptor(EGFR)mutations,with L858R and exon-19 deletions(19-Del)accounting for 90%of cases.EGFR tyrosine kinase inhibitors(TKls)showed significant efficacy against common EGFR mutations.However,the therapeutic relevance of uncommon EGFR mutations remained insufficiently investigated.EGFR fusions are extremely rare(0.05%-0.13%)in NSCLC,and Konduri group reported only 5 EGFR fusions from 10,097 patients.i2Additional EGFR'fusions were reported in NSCLC,3,4 all of which were oncogenic drivers and sensitive to EGFR TKls.Herein,we reported an NSCLC patient with leptomeningeal metastasis(LM)who acquired a novel EGFR-SEPT14 fusion during TKI resistance and showed promising responses to certain EGFR TKls and intrathecal pemetrexed(IP).
